News

Luminoah closes $6M Series A round

Charlottesville medical device company Luminoah Inc. has closed a $6 million Series A round it says it will use to complete the development of its mobile feeding tube device that collects data.

The round was led by Charlottesville’s Fry’s Path Capital and included participation from Arlington’s Sands Capital, Charlottesville’s CAV Angels, Virginia Beach’s 757 Angels and Richmond’s Virginia Venture Partners — the equity investment arm of the Virginia Innovation Partnership Corp.

Luminoah, which took top honors at the Light House Labs’ Demo Day competition last month, says its device lets patients to keep a more mobile lifestyle while on a feeding tube. Its data-tracking features also allow remote patient monitoring.

CEO Neal Piper started the company after his young son was diagnosed with cancer and required a constraining feeding tube.

“It’s just a no-brainer to let a kid be active while you pump nutrition into their stomach,” Piper told Richmond Inno last month.

Piper said the goal is to apply for Food and Drug Administration approval in 2024. Luminoah wants to go after the pediatric home health care market initially, but also seeks to move into senior and rehabilitation markets. The company says the enteral feeding technology market is worth about $12 billion and that half-a-million children could benefit from its product.

Learn more here.

Recent News

10/13/2025

InBio Secures $3.5 Million NIH Grant to Advance Allergy Research

InBio, a global leader in allergy research, was recently awarded a $3.5 million R01 grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This funding supports a groundbreaking initiative to develop innovative immunotherapeutic tools targeting allergens from house dust mites, cats, and dogs—major contributors to

10/09/2025

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs

AstraZeneca announces that it will invest $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500m to support the enhanced manufacturing capability of a broader range of medicines including cancer treatments. This is part of the historic $50 billion investment announced in July 2025. The new facility will be located at

10/09/2025

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the successful completion of the analytical validation of a cheek swab collection method for testing patients for both clinical trial usage as well as future commercial application. This major step marks a